161 related articles for article (PubMed ID: 21432866)
21. Reduced alpha- and beta-catenin expression predicts shortened survival in local prostate cancer.
Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
Anticancer Res; 2005; 25(6C):4707-12. PubMed ID: 16334164
[TBL] [Abstract][Full Text] [Related]
22. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
23. Low p27 expression predicts poor disease-free survival in patients with prostate cancer.
Yang RM; Naitoh J; Murphy M; Wang HJ; Phillipson J; deKernion JB; Loda M; Reiter RE
J Urol; 1998 Mar; 159(3):941-5. PubMed ID: 9474188
[TBL] [Abstract][Full Text] [Related]
24. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
25. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
26. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
[TBL] [Abstract][Full Text] [Related]
27. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy.
Freedland SJ; Aronson WJ; Presti JC; Amling CL; Terris MK; Trock B; Kane CJ
Cancer; 2004 Apr; 100(8):1633-8. PubMed ID: 15073850
[TBL] [Abstract][Full Text] [Related]
28. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy.
Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Koutsilieris M
Anticancer Res; 2005; 25(4):3123-33. PubMed ID: 16080576
[TBL] [Abstract][Full Text] [Related]
30. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
[TBL] [Abstract][Full Text] [Related]
31. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
[TBL] [Abstract][Full Text] [Related]
32. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection.
Gao X; Mohideen N; Flanigan RC; Waters WB; Wojcik EM; Leman CR
J Urol; 2000 Dec; 164(6):1982-6. PubMed ID: 11061896
[TBL] [Abstract][Full Text] [Related]
33. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
34. Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
Hoogland AM; Dahlman A; Vissers KJ; Wolters T; Schröder FH; Roobol MJ; Bjartell AS; van Leenders GJ
BJU Int; 2011 Oct; 108(8):1356-62. PubMed ID: 21410630
[TBL] [Abstract][Full Text] [Related]
35. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
36. Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status.
Masterson TA; Pettus JA; Middleton RG; Stephenson RA
Urology; 2005 Jul; 66(1):152-5. PubMed ID: 15992904
[TBL] [Abstract][Full Text] [Related]
37. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
Bloom KD; Richie JP; Schultz D; Renshaw A; Saegaert T; D'amico AV
Urology; 2004 Feb; 63(2):333-6. PubMed ID: 14972484
[TBL] [Abstract][Full Text] [Related]
38. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy.
Behnsawy HM; Miyake H; Harada K; Fujisawa M
BJU Int; 2013 Jan; 111(1):30-7. PubMed ID: 23107154
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
